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Comparison of fixed-dose weight-adjusted unfractionated heparin and
low-molecular-weight heparin for acute treatment of venous
thromboembolism
Kearon C, Ginsberg JS, Julian JA; and the Fixed-Dose Heparin Investiga-
tors. JAMA 2006;296:936-42.
Conclusion: Low-molecular-weight heparin and fixed-dose subcuta-
neous unfractionated heparin are equally as effective for outpatient treat-
ment of acute venous thromboembolism (VTE).
Summary: The authors sought to determine if weight-adjusted, fixed-
dose subcutaneous unfractionated heparin would be as effective and safe as
low-molecular-weight heparin in the treatment of VTE. This was a random-
ized, adjudicated, blinded, open-labeled, noninferiority trial. There were
708 patients, all 18 years of age, and all had acute VTE. The study was
conducted in six university-affiliated medical centers in New Zealand and
Canada. The study ran from September 1998 through February 2004.
Patients treated with weight-adjusted unfractionated heparin (n 
345) received an initial dose of 333 U/kg, followed by fixed doses of 250
U/kg every 12 hours. Patients treated with low-molecular-weight heparin
(n  352) received either dalteparin or enoxaparin. Low-molecular-weight
heparin was administered subcutaneously at a dose of 100 IU/kg every 12
hours. Patients treated with either unfractionated or low-molecular-weight
heparin could be treated as outpatients. Both forms of treatment overlapped
with warfarin therapy for 3 months. The principal end point of the study was
recurrent VTE or major bleeding within 10 days.
A study drug was given for a mean of 6.6 days in the unfractionated
heparin group and a mean of 7.1 days in the low-molecular-weight heparin
group. There were 12 episodes (3.4%) of recurrent VTE in the low-
molecular-weight heparin group and 13 episodes (3.8%) in the unfraction-
ated heparin group. This was an absolute difference of 0.4% (95% confidence
interval, 2.6% to 3.3%). Equal amounts of major bleeding occurred
between the two groups, with major bleeding in the first 10 days of
treatment in four patients (1.1%) in the unfractionated heparin group and in
five patients (1.4%) in the low-molecular-weight heparin group (95% confi-
dence interval, 2.3% to 1.7%). Treatment was administered outside of a
hospital in 68% of the patients treated with low-molecular-weight heparin
and 72% of the patients treated with weight-adjusted unfractionated
heparin.
In patients treated with unfractionated heparin, activated partial
thromboplastin time (aPTT) was measured halfway between injections at a
mean of 2.8 days after starting therapy. The aPTT values were 60
seconds in 39 patients, 60 to 85 seconds in 37, and 85 seconds in 121
patients. Levels of aPTT were not associated with recurrent VTE or
major bleeding.
Comment: The data suggest unfractionated heparin administered
subcutaneously on a weight-based dosage regimen and low-molecular-
weight heparin can provide equal protection against recurrent VTE in
patients with acute VTE. The study has significant implications for all
patients who are unable to afford the cost of low-molecular-weight heparin
as an outpatient. Perhaps such patients can be treated at home with weight-
based, fixed doses of unfractionated heparin? This will remove a potential
barrier to outpatient treatment of acute VTE in patients who cannot afford
the cost of low-molecular-weight heparin as an outpatient.
Femoral vessel injuries: analysis of factors predictive of outcomes
Asensio JA, Kuncir EJ, Garcia-Nunez LN, et al. J Am Coll Surg 2006;2003:
512-20.
Conclusion: There is both a high survival and complication rate for
treatment of femoral vessel injuries.
Summary: This was a retrospective study of patients admitted during a
132-month period (January 1, 1992 throughDecember 31, 2002) at a large
level 1 urban trauma center. Univariant and multivariant analysis were used
to determine predictors of outcome after femoral vessel injury.
There were 204 patients with 298 vessel injuries consisting of 204
arterial and 94 venous injuries. Mean patient age was 29  13 years. Mean
injury severity score was 17  8. Eighty-six percent of injuries (n  176)
were penetrating, and 14% (n  28) were blunt injuries.
Numerous techniques were used for both arterial and venous repairs. In
arterial repairs, reverse saphenous vein grafts were used in 53%. Primary
repair of the injury was performed in 26%. A polytetrafluoroethylene graft
was placed in 10.2%. The femoral vessel was ligated in 6.4%. With respect to
femoral venous injuries, 52% were ligated, 44% underwent primary repair,
and 4% underwent bypass. Twenty-seven percent of the patients underwent
fasciotomy of the calf, and 12% underwent fasciotomy of the thigh. There
were six acute amputations and no delayed amputations. Overall survival was
91%; when emergency department thoracotomy deaths were excluded,
adjusted survival was 95%.
Complications occurred in 47 patients (23%). The most common
complication was wound infection (n 31), followed by venous thrombosis
(n  6). Arterial thrombosis occurred in only one patient. Predictors of
postoperative complication included interoperative hypertension, arterial
injury, long bone facture, and thoracic injury. Predictors of mortality were
age45 years, injury severity score25, common femoral artery injury, and
the combination of venous and abdominal injuries.
Comment:Reports such as this do not provide much in the way of new
insights. Predictors of mortality, complications, and the types of complica-
tions are what one would expect. It is interesting, however, to note the very
high survival rate for patients with such injuries treated in a level 1 trauma
center.
Plasma d-lactate as a potential early marker for colon ischaemia after
open aortic reconstruction
Assadian A, Assadian O, Senekowitsch C, et al. Eur J Vasc Endovasc Surg
2006;31:470-4.
Conclusion: Plasma d-lactate levels are a useful marker to detect
ischemic colitis after aortic surgery.
Summary: Ischemic colitis after aortic surgery has mortality rates of up
to 90%. Ischemic colitis must currently be diagnosed with endoscopic
techniques. D-lactate and bacterial endotoxin have been reported in animal
studies as markers of breakdown of the mucosal barrier after intestinal
hypoperfusion. The authors sought to evaluate potential efficacy of these
markers in clinical practice after aortic surgery. This was a prospective cohort
study designed to assess in patients the association between histologically
evaluated colon ischemia and plasma levels of endotoxin and d-lactate after
open aortic reconstruction.
Between February and April 2003, 12 consecutive patients underwent
aortic surgery; six had emergent procedures and six had elective aortic
surgery. Endotoxin and d-lactate levels were measured according to a
standardized protocol, and histologic samples of the colon were obtained by
sigmoidoscopy on days 4 to 6 after surgery or earlier, if clinically indicated.
Two hours postoperatively, elevated plasma levels of d-lactate were
found in patients with histologically proven ischemic colitis. Peak d-lactate
levels occurred on postoperative days 1 and 2. No alterations were noted in
plasma endotoxin in patients with or without ischemic colitis. Four patients
had histologically proven ischemic colitis: two died on postoperative day 3,
one died on postoperative day 31, and one patient was discharged home. All
episodes of ischemic colitis occurred in patients with ruptured abdominal
aortic aneurysms. Elevations in d-lactate level proceeded clinical decline
from colonic ischemia in the three patients who died.
Comment: Obviously, no definite conclusions can be made from this
small pilot study. However, the fact d-lactate levels were elevated in patients
with clinically important colonic ischemia before their clinical decline—and
were not elevated in patients without colonic ischemia—suggests a poten-
tially important role for this serum marker.
Plasma sphingomyelin in subclinical atherosclerosis: findings from the
multi-ethic study of atherosclerosis
Nelson JC, Jiang X-C, Tall A, et al. Am J Epidemiol 2006;163:903-12.
Conclusion: Plasma sphingomyelin is a component of the biologic
pathway mediating risk for subclinical atherosclerosis that is normally attrib-
utable to standard cardiovascular risk factors.
Summary: Plasma sphingomyelin is an independent risk factor for
coronary heart disease. In this study, the authors sought to determine the
relation of plasma sphingomyelin to subclinical atherosclerotic disease. The
relationship between plasma sphingomyelin and three different measure-
ments of subclinical cardiovascular disease (ankle and arm blood pressure
index, carotid intimal-medial thickness, and Agatston coronary artery and
calcium score) were assessed. Study subjects included 6814 asymptomatic
middle-aged adults from a multiethnic study of atherosclerosis first initiated
in 2000.
Plasma sphingomyelin levels correlated positively with lipid levels and
the Framingham risk score (P  .01 for both). The mean level of plasma
sphingomyelin was higher in women than men (50 16 mg/dL vs 45 15
mg/dL, P  .01). Plasma sphingomyelin levels were higher in never
(4916 mg/dL) vs current smokers (4517 mg/dL, P  .01). Levels of
subclinical vascular disease as assessed by all three measures were higher in
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